Mylan (MYL) Position Raised by LSV Asset Management

LSV Asset Management increased its position in shares of Mylan (NASDAQ:MYL) by 2.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 600,295 shares of the company’s stock after purchasing an additional 16,400 shares during the period. LSV Asset Management’s holdings in Mylan were worth $25,398,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in MYL. Pzena Investment Management LLC increased its holdings in shares of Mylan by 84.1% in the third quarter. Pzena Investment Management LLC now owns 22,721,384 shares of the company’s stock valued at $712,770,000 after buying an additional 10,381,697 shares in the last quarter. Greenlight Capital Inc. increased its holdings in shares of Mylan by 0.4% in the third quarter. Greenlight Capital Inc. now owns 10,744,307 shares of the company’s stock valued at $337,048,000 after buying an additional 42,600 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Mylan by 6.0% in the third quarter. Bank of New York Mellon Corp now owns 4,095,700 shares of the company’s stock valued at $128,481,000 after buying an additional 232,762 shares in the last quarter. Orbimed Advisors LLC increased its holdings in shares of Mylan by 20.9% in the third quarter. Orbimed Advisors LLC now owns 3,601,100 shares of the company’s stock valued at $112,967,000 after buying an additional 621,900 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Mylan by 20.8% in the third quarter. Dimensional Fund Advisors LP now owns 3,553,480 shares of the company’s stock valued at $111,450,000 after buying an additional 612,513 shares in the last quarter. 75.00% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts have issued reports on the company. BidaskClub cut Mylan from a “strong-buy” rating to a “buy” rating in a report on Friday, January 26th. Susquehanna Bancshares reaffirmed a “positive” rating and issued a $55.00 price target (up previously from $47.00) on shares of Mylan in a report on Thursday, January 25th. Zacks Investment Research raised Mylan from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Guggenheim assumed coverage on Mylan in a report on Tuesday, December 12th. They issued a “buy” rating and a $59.00 price target on the stock. Finally, Wells Fargo & Co set a $43.00 price target on Mylan and gave the company a “hold” rating in a report on Thursday, January 18th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $44.65.

In other news, CEO Heather M. Bresch sold 75,000 shares of the business’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total transaction of $3,375,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.69% of the company’s stock.

Mylan (MYL) opened at $40.45 on Thursday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.95 and a current ratio of 1.46. Mylan has a fifty-two week low of $29.39 and a fifty-two week high of $47.82. The company has a market cap of $21,983.16, a price-to-earnings ratio of 25.12, a PEG ratio of 1.11 and a beta of 1.35.

Mylan (NASDAQ:MYL) last posted its quarterly earnings results on Monday, November 6th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.10). Mylan had a net margin of 7.28% and a return on equity of 20.63%. The company had revenue of $2.99 billion for the quarter, compared to analysts’ expectations of $3.09 billion. During the same quarter in the prior year, the firm earned $1.38 earnings per share. The company’s revenue was down 2.3% on a year-over-year basis. sell-side analysts predict that Mylan will post 4.55 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Mylan (MYL) Position Raised by LSV Asset Management” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://sportsperspectives.com/2018/02/08/mylan-myl-position-raised-by-lsv-asset-management.html.

Mylan Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply